Innate Pharma S.A. (IPHA) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 5, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-K for FY2025, filed Apr 1, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the IPHA SEC filings page.
Innate Pharma S.A. (IPHA) reported $50.0M in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. All figures are derived from SEC filings (10-K and 10-Q reports).
Reported FY2025 revenue of $50M establishes scale, but the available figures cannot explain how this business is financed or operates.
The key analytical limitation is that revenue is the only validated operating measure, leaving no defensible connection between sales scale, profitability, cash conversion, or balance-sheet funding.
At
Some figures from recent filings were inconsistent and were omitted from this summary.
Financial Health Signals
We are recalculating Innate Pharma S.A.'s peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
Innate Pharma S.A. generated $50.0M in revenue in fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
None of these metrics is reported for fiscal year 2025.
Capital Allocation
None of these metrics is reported for fiscal year 2025.
IPHA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2510-K |
|---|---|
| Revenue | $50.0M |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Innate Pharma S.A. IPHA | FY2025 | $50.0M | N/A | N/A | $176.5M | — |
| NeOnc Technologies Holdings, Inc. NTHI | FY2025 | $40K | N/A | N/A | $86.1M | — |
| C4 Therapeutics, Inc. CCCC | FY2025 | $35.9M | -$105.0M | N/A | $362.9M | 65/100 |
| Elicio Therapeutics, Inc. ELTX | FY2025 | N/A | -$39.6M | N/A | $50.5M | — |
| Enanta Pharmaceuticals, Inc ENTA | FY2025 | $65.3M | -$81.9M | N/A | $377.5M | 63/100 |
| Aclaris Therapeutics, Inc. ACRS | FY2025 | $7.8M | -$64.9M | N/A | $646.2M | 55/100 |
Where Innate Pharma S.A. Ranks
Frequently Asked Questions
What is Innate Pharma S.A.'s annual revenue?
Innate Pharma S.A. (IPHA) reported $50.0M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
What is Innate Pharma S.A.'s P/E ratio?
Innate Pharma S.A. (IPHA) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $176.5M as of Oct 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Innate Pharma S.A.'s price-to-sales ratio?
Innate Pharma S.A. (IPHA) trades at 3.5x sales, its market capitalization divided by revenue of $50.0M revenue, FY2025. The market capitalization is $176.5M as of Oct 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.